CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SEVENTH

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],

HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT

MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL.

SEVENTH AMENDMENT TO SUPPLY

amendment ( Seventh Amendment ) to the Supply Agreement by and between MannKind Corporation ( MannKind ) and Amphastar Pharmaceuticals, Inc. ( Amphastar ), originally dated July 31, 2014 and as

previously amended on October 31, 2014, November 9, 2016 , April11, 2018, December 24, 2018, August 2, 2019 , and May 24, 2021, (collectively, the Agreement ), is hereby made as of

the December 22, 2023, by and between MannKind on the one hand, and on the other hand, Amphastar.

WHEREAS, MannKind and Amphastar entered into the Agreement pursuant to which Amphastar is to manufacture and supply the Product to

MannKind, and MannKind is to purchase certain minimum quantities of the Product; and

WHEREAS MannKind and Amphastar have

determined it to be mutually beneficial to amend the Agreement as set forth herein.

NOW, THEREFORE, for good and valuable

consideration, MannKind and Amphastar hereby agree to amend the Agreement as follows:

1. Definitions. Unless otherwise

defined herein, each of the capitalized terms used in this Seventh Amendment shall have the definition and meaning ascribed to it in the Agreement.

2. The definitions in Section 1 of the Agreement are amended by adding the following provisions at the end of

Section 1 and not in alphabetical order:

2.1. New Section 1.16 is added as follows: Capacity Fee means

the amount MannKind will pay to Amphastar France Pharmaceuticals ( AFP ) every calendar quarter. The Capacity Fee is for a full calendar quarter, including the calendar quarter that MannKind receives FDA approval

for MannKind to use the Product produced with inclusion bodies that are manufactured by Amphastar. For example, if FDA approval is on Feb. 15, 2026, then the full Capacity Fee for the first calendar quarter is due in accordance with

the table in Section 6.1, following which Year 1 would start on April 1, 2026.

2.2. New Section 1.17 is added

as follows: Year 1 means the year that starts on the first day of the calendar quarter after MannKind receives FDA approval to use the Product produced with inclusion bodies that are manufactured by Amphastar. For example,

if such FDA approval is on February 15, then Year 1 will commence on the subsequent April 1 and will end on March 31 of the following year. Year 2, 3, and so on, will be 12-month

periods that commence on each anniversary of Year 1.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],

HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT

MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL.

3. The table in Section 6.1 of Agreement, shall be deleted

and replaced in its entirety with the following:

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],

HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT

MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL.

4. Section 10.1 of the Agreement shall be extended until the later of

(a) December 31, 2035 or (b) until the completion of total Purchase Commitment Quantities as provided in the table of Section 6.1. All other terms and conditions in Section 10.1 shall remain in full force and effect.

5. Final Agreement. From and after the execution of this Seventh Amendment, all references in the Agreement (or in the Seventh

Amendment) to this Agreement, hereof, herein, hereto, and similar words or phrases shall mean and refer to the Agreement as amended by this Seventh Amendment. The Agreement as amended by this Seventh

Amendment constitutes the entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this Seventh Amendment, all other terms and conditions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, each of MannKind and Amphastar has caused this Seventh Amendment to be executed by their duly authorized